登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，2月3日，A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2021-02-25

  • A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
    Qingrui Huang, Kai Ji, Siyu Tian, Fengze Wang, Baoying Huang, Zhou Tong, Shuguang Tan, Junfeng Hao, Qihui Wang, Wenjie Tan, George F. Gao & Jinghua Yan
    Nature Communications volume 12, Article number: 776 (2021)

    Abstract
    The rapid expansion of the COVID-19 pandemic has made the development of a SARS-CoV-2 vaccine a global health and economic priority. Taking advantage of versatility and rapid development, three SARS-CoV-2 mRNA vaccine candidates have entered clinical trials with a two-dose immunization regimen. However, the waning antibody response in convalescent patients after SARS-CoV-2 infection and the emergence of human re-infection have raised widespread concerns about a possible short duration of SARS-CoV-2 vaccine protection. Here, we developed a nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD, termed as mRNA-RBD. A single immunization of mRNA-RBD elicited both robust neutralizing antibody and cellular responses, and conferred a near-complete protection against wild SARS-CoV-2 infection in the lungs of hACE2 transgenic mice. Noticeably, the high levels of neutralizing antibodies in BALB/c mice induced by mRNA-RBD vaccination were maintained for at least 6.5 months and conferred a long-term notable protection for hACE2 transgenic mice against SARS-CoV-2 infection in a sera transfer study. These data demonstrated that a single dose of mRNA-RBD provided long-term protection against SARS-CoV-2 challenge.

  • 原文来源：https://www.nature.com/articles/s41467-021-21037-2
168浏览量
原文链接
相关报告

  • 《Prnewswire，2月14日，Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-23
    • TAIZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recogen Biotechnology Co., Ltd. (Recogen) on lyophilized mRNA vaccine. The lyophilized mRNA-LNP nanoparticle vaccine is delivered by an LNP delivery system and achieved stability at 4℃ and 25℃ based on a self-developed lyophilization technology. The vaccine can be stored and transported in conventional cold chain conditions, greatly improving the accessibility of mRNA vaccine. The results have been on the preprint server bioRxiv According to this paper, Recogen developed the lyophilized mRNA-LNP nanoparticle vaccine targeting wild-type, Delta and Omicron SARS-CoV-2 variant, and the data showed that the lyophilized process did not affect the key physicochemical parameters, biological activity and immunogenicity of the vaccine. Notably, the Delta-specific mRNA vaccine can induce a high-level neutralization response in mice against both the wild-type and the current global pandemic strain Omicron. A virus challenge study of hACE2 transgenic mice shows the lyophilized mRNA-Delta vaccine is highly immunogenic and can fully protect the challenged mice from SARS-COV-2 infection and clear the virus. Vaccines have become the world's most cost-effective tool to respond to the COVID-19. As of now, more than 10 billion doses of COVID-19 vaccine have been administered globally. However, only 10% of people in low-income countries have received at least one dose of vaccine. Therefore, it is particularly important to develop an mRNA vaccine that can be transported in conventional cold-chain and be stored at 2℃~8℃, or at room temperature stably for broad application. Recogen successfully achieved the lyophilization of mRNA-LNP vaccine. This lyophilization platform could significantly improve the accessibility of mRNA vaccines or therapeutics, particularly in remote regions. The paper links: https://www.biorxiv.org/content/10.1101/2022.02.10.479867v2.full.pdf
    106浏览量
    原文链接

  • 《2月3日_单剂量mRNA疫苗可长期保护hACE2转基因小鼠免受SARS-CoV-2感染》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-02-25
    • Nature Communications于2月3日发表了中国科学院和中国科学院大学等的文章“A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2”，文章描述了一种单剂量mRNA疫苗为hACE2转基因小鼠抗SARS-CoV-2提供了长期保护。 文章称，COVID-19大流行范围的迅速扩大使SARS-CoV-2疫苗的开发成为全球卫生和经济优先事项。利用通用性和快速发展的优势，三种SARS-CoV-2 mRNA候选疫苗已进入临床试验，免疫方案为两剂。然而，由于SARS-CoV-2感染后恢复期患者的抗体反应减弱以及人类再感染的出现，引起了人们对SARS-CoV-2疫苗保护期可能较短的广泛关注。该研究开发了一种脂质包裹形式的核苷修饰的mRNA疫苗，该疫苗编码SARS-CoV-2受体结合域（RBD），称为mRNA-RBD。mRNA的单次免疫接种可引起强大的中和抗体和细胞应答，并赋予hACE2转基因小鼠肺部对野生SARS-CoV-2感染近乎的完全保护。值得注意的是，在一项血清转移研究中，mRNA-RBD疫苗诱导的BALB/c小鼠体内的高水平中和抗体至少维持了6.5个月，并为hACE2转基因小鼠抗SARS-CoV-2感染提供了长期的显著保护。这些数据表明，单剂量的mRNA-RBD可提供针对SARS-CoV-2攻击的长期保护。 来源：https://www.nature.com/articles/s41467-021-21037-2
    48浏览量
    原文链接